-1.18%
4.03%
1.94%
20.79%
20.79%
80.59%
94.84%
AI Spotlight on SOBI
Company Description
Swedish Orphan Biovitrum AB (publ), an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally.It offers Alprolix for haemophilia B; Doptelet treatment of thrombocytopenia; Elocta for haemophilia A; Gamifant for hemophagocytic lymphohistiocytosis(HLH); Kineret for cryopyrin associated periodic syndrome, rheumatoid arthritis, and still's disease; Orfadin to treat hereditary tyrosinaemia type-1; and Synagis for serious lower respiratory tract infection.The company It also provides other products, such as Akynzeo, Aloxi, Ammonul, Betapred, Caphosol, Fibclot, IVheBex, and Willfact.
In addition, it develops drug substance for ReFacto AF/Xyntha for Pfizer; BIVV001 for haemophilia A; and Nirsevimab for respiratory syncytial virus.The company has a strategic collaboration with Apellis Pharmaceuticals Inc.to develop pegcetacoplan for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria.
Swedish Orphan Biovitrum AB (publ) is headquartered in Solna, Sweden.
Market Data
| Last Price | 335.8 |
| Change Percentage | -1.18% |
| Open | 340.4 |
| Previous Close | 339.8 |
| Market Cap ( Millions) | 115326 |
| Volume | 418630 |
| Year High | 354.4 |
| Year Low | 243.2 |
| M A 50 | 318.57 |
| M A 200 | 302.2 |
Financial Ratios
| FCF Yield | 2.98% |
| Dividend Yield | 0.00% |
| ROE | 9.82% |
| Debt / Equity | 48.17% |
| Net Debt / EBIDTA | 184.94% |
| Price To Book | 3.11 |
| Price Earnings Ratio | 32.78 |
| Price To FCF | 33.6 |
| Price To sales | 4.53 |
| EV / EBITDA | 14.2 |
News
- Jan -21 - Invitation: Sobi's Q4 and FY 2024 report
- Dec -13 - FDA accepts Sobi North America’s thrombocytopenia therapy sNDA
- Dec -12 - Sobi Announces FDA Acceptance of New Drug Application for Avatrombopag (DOPTELET®) for the Treatment of Pediatric Immune Thrombocytopenia
- Nov -18 - High Growth Tech Stocks To Watch This November 2024
- Nov -11 - Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
- Nov -07 - Sobi to present new data across its immunology portfolio at the ACR Convergence 2024
- Nov -04 - David Meek is proposed as new Chair of the Board of Directors of Sobi
- Oct -30 - New data for emapalumab in the treatment of macrophage activation syndrome to be presented at the ACR conference
- Oct -27 - Pivotal VALIANT results presented at Kidney Week show pegcetacoplan treatment effect in patients with C3G / primary IC-MPGN
- Oct -25 - Invitation: Sobi's Aspaveli® and the Phase 3 VALIANT data in Nephrology call
- Oct -25 - Swedish Orphan Biovitrum AB (BIOVF) Q3 2024 Earnings Call Highlights: Robust Growth and ...
- Oct -24 - Sobi Q3 2024 report: Strong growth and significant pipeline momentum
- Oct -18 - High Growth Tech Stocks In Sweden With Promising Potential
- Oct -09 - Invitation: Sobi's Q3 2024 report
- Oct -01 - Exploring Sweden's High Growth Tech Giants
- Sep -30 - High Growth Tech Stocks In Sweden To Watch This September 2024
- Sep -19 - High Growth Tech Stocks In Sweden Embracer Group And Two More
- Sep -18 - Exploring 3 High Growth Tech Stocks In Sweden
- Sep -17 - High Growth Tech Stocks In Sweden For September 2024
- Sep -16 - High Growth Tech Stocks in Sweden to Watch This September 2024
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Haematology
Expected Growth : 8 %
What the company do ?
Haematology from Swedish Orphan Biovitrum AB (publ) refers to the study, diagnosis, treatment, and prevention of disorders related to the blood and its components.
Why we expect these perspectives ?
Strong demand for rare disease treatments, increasing diagnosis rates, and growing awareness of bleeding disorders drive Haematology segment growth. Sobi's strong pipeline, strategic partnerships, and expanding geographic presence also contribute to the 8% growth rate.
Segment n°2 -> Immunology
Expected Growth : 9 %
What the company do ?
Immunology from Swedish Orphan Biovitrum AB (publ) refers to the study and treatment of immune system disorders, focusing on rare and serious diseases.
Why we expect these perspectives ?
Strong demand for rare disease treatments, increasing prevalence of immunological disorders, and strategic partnerships drive growth for Immunology segment of Swedish Orphan Biovitrum AB (publ), with a 9% growth rate. Novel therapies and pipeline advancements also contribute to this growth, as the company expands its presence in the global immunology market.
Segment n°3 -> Specialty Care
Expected Growth : 10 %
What the company do ?
Specialty Care from Swedish Orphan Biovitrum AB (publ) focuses on developing and commercializing innovative therapies for rare diseases and unmet medical needs.
Why we expect these perspectives ?
Swedish Orphan Biovitrum AB's Specialty Care segment growth is driven by increasing demand for rare disease treatments, expansion into new markets, and strategic partnerships. The company's strong pipeline, including promising therapies for hemophilia and immunology, contributes to its 10% growth. Additionally, investments in digital health and personalized medicine enhance patient outcomes, further fueling growth.
Swedish Orphan Biovitrum Ab (Publ) Products
| Product Range | What is it ? |
|---|---|
| Kineret | Kineret is a recombinant human interleukin-1 receptor antagonist used to treat rheumatoid arthritis, cryopyrin-associated periodic syndromes and other inflammatory diseases. |
| Orfadin | Orfadin is a medication used to treat hereditary tyrosinemia type 1, a rare genetic disorder that affects the breakdown of the amino acid tyrosine. |
| Kepivance | Kepivance is a recombinant human keratinocyte growth factor used to reduce the severity of oral mucositis in patients with hematologic cancers undergoing high-dose chemotherapy and radiation therapy. |
| Synagis | Synagis is a medication used to prevent serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in high-risk infants and young children. |
Swedish Orphan Biovitrum AB (publ)'s Porter Forces
Threat Of Substitutes
The threat of substitutes for Swedish Orphan Biovitrum AB (publ) is moderate due to the presence of alternative treatments and therapies for rare diseases.
Bargaining Power Of Customers
The bargaining power of customers is low due to the specialized nature of Swedish Orphan Biovitrum AB (publ)'s products and the lack of alternative treatment options.
Bargaining Power Of Suppliers
The bargaining power of suppliers is moderate due to the dependence on a few key suppliers for raw materials and the potential for supply chain disruptions.
Threat Of New Entrants
The threat of new entrants is low due to the high barriers to entry in the biotechnology industry, including the need for significant research and development investments.
Intensity Of Rivalry
The intensity of rivalry is high due to the competitive nature of the biotechnology industry and the presence of established players.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 37.50% |
| Debt Cost | 5.20% |
| Equity Weight | 62.50% |
| Equity Cost | 5.20% |
| WACC | 5.20% |
| Leverage | 59.99% |
Swedish Orphan Biovitrum AB (publ) : Quality Control
Swedish Orphan Biovitrum AB (publ) passed 2 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| IPN.PA | Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors … |
| ALM.MC | Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for … |
| HIK.L | Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage … |
| SFZN.SW | Siegfried Holding AG engages in the life sciences business worldwide. The company develops and produces active pharmaceutical ingredients (APIs) and intermediates, as well as finished dosage forms, including solid oral … |
| ALVO | Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Ipsen
A-Score
1-Year Total Return ->
🥈
Hikma Pharmaceuticals
A-Score
1-Year Total Return ->
🥉
Almirall
A-Score
1-Year Total Return ->
4
Siegfried Holding
A-Score
1-Year Total Return ->
5
Sobi
A-Score
1-Year Total Return ->
6
